GAMMA Investing’s Cytek Biosciences CTKB Stock Holding History

GAMMA Investing’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.38K	Sell	989 -642	-39%	-$2.74K	﹤0.01%	3523
2026 Q1	$7.13K	Buy	1,631 +1,114	+215%	+$5.26K	﹤0.01%	3226
2025 Q4	$2.61K	Buy	+517	New	+$2.4K	﹤0.01%	3527
2025 Q2	–	Sell	-718	Closed	-$2.88K	–	3797
2025 Q1	$2.88K	Sell	718 -4,214	-85%	-$21.8K	﹤0.01%	3295
2024 Q4	$32K	Buy	4,932 +3,635	+280%	+$21.7K	﹤0.01%	2002
2024 Q3	$7.18K	Buy	1,297 +229	+21%	+$1.3K	﹤0.01%	2590
2024 Q2	$5.96K	Buy	1,068 +172	+19%	+$1.03K	﹤0.01%	2498
2024 Q1	$6.01K	Sell	896 -704	-44%	-$5.57K	﹤0.01%	2320
2023 Q4	$12.1K	Buy	+1,600	New	+$10.1K	﹤0.01%	1799

Other funds holding CTKB

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return

NAM

NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing's CTKB Position: Q2 2026 in Review

GAMMA Investing reduced its Cytek Biosciences (CTKB) stake by 39% in Q2 2026, selling an estimated $2.74K and leaving 989 shares worth $4.38K. The position accounts for ﹤0.01% of the portfolio, ranked #3523.

GAMMA Investing first reported a position in CTKB in Q4 2023 and has held it in 9 quarters since. The position peaked at $32K in Q4 2024. 14 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

GAMMA Investing held 989 shares of Cytek Biosciences worth $4.38K as of Q2 2026.
GAMMA Investing sold 642 Cytek Biosciences shares in Q2 2026, an estimated $2.74K.
Cytek Biosciences made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3523 holding.
GAMMA Investing first reported a position in Cytek Biosciences in Q4 2023 and has held it in 9 quarters since.
GAMMA Investing's Cytek Biosciences position peaked at $32K in Q4 2024.
14 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.